|
|
Reference
|
|
  
|
Agis-Torres, A., Sollhuber, M., Fernandez, M., Sanchez-Montero, J.M. (2014) Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease. Current Neuropharmacology, 12(1): 2-36
|
|
1 
|
Ascano, M., Mukherjee, N., Bandaru, P., Miller, J.B., Nusbaum, J.D., Corcoran, D.L., Langlois, C., Munschauer, M., Dewell, S., Hafner, M., Williams, Z., Ohler, U., Tuschl, T. (2012) FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature, 492(7429): 382-6
|
|
2
|
Bagni, C., Tassone, F., Neri, G., Hagerman, R. (2012) Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. Journal of Clinical Investigation, 122(12): 4314-4322
|
|
|
Bailey, D.B., Raspa, M., Wheeler, A., Edwards, A., Bishop, E., Bann, C., Borasky, D., Appelbaum, P.S. (2014) Parent ratings of ability to consent for clinical trials in fragile X syndrome. Journal of empirical research on human research ethics, 9(3): 18-28
|
|
1
|
Bassell, G.J., Warren, S.T. (2008) Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron, 60(2): 201-14
|
|
|
Bear, M.F., Huber, K.M., Warren, S.T. (2004) The mGluR theory of fragile X mental retardation. Trends in Neurosciences, 27(7): 370-377
|
|
|
Berry-Kravis, E., Budimirovic, D., i dr. (2016) Arbaclofen in fragile X syndrome: Results of phase 3 trials. J Neurodev Disord, under review JNDD-D-16-00048, An original invited paper
|
|
|
Black, J. (1988) Drugs from emasculated hormones: The principles of synoptic antagonism. u: Nobel Lecture
|
|
|
Blake-Anson, D., Junyi, M., Jia-Qiang, H. (2009) Identifying cardiotoxic compounds. Genetic Engineering & Biotechnology News, TechNote; 29 (9): 34-35
|
|
|
Bosch, F., Rosich, L. (2008) The Contributions of Paul Ehrlich to Pharmacology: A Tribute on the Occasion of the Centenary of His Nobel Prize. Pharmacology, 82(3): 171-179
|
|
|
Budimirovic, D., i dr. (2016) Updates report on tools to measure outcomes of clinical trials in fragile X syndrome. J Neurodev Disord, under review JNDD-D-16-00077, An invited review
|
|
1
|
Budimirovic, D.B., Subramanian, M. (2016) Neurobiology of autism and intellectual disability: Fragile X syndrome. u: Johnston M.V. [ur.] Neurobiology of Disease, New York: Oxford University Press, p. 375-384
|
|
|
Budimirovic, D.B., Phan, D.Q. (2016) Challenges in translating terapeutic frontiers in clinical trials: Where are we now and what’s next?. Madridge J Neuro Sci, 1(1): e1-e3
|
|
2
|
Budimirovic, D.B., Bukelis, I., Cox, C., Gray, R.M., Tierney, E., Kaufmann, W.E. (2006) Autism spectrum disorder in Fragile X syndrome: Differential contribution of adaptive socialization and social withdrawal. American Journal of Medical Genetics Part A, 140A(17): 1814-1826
|
|
2
|
Budimirovic, D.B., Kaufmann, W.E. (2011) What can we learn about autism from studying fragile X syndrome?. Developmental neuroscience, 33(5): 379-94
|
|
|
Budimirović, D.B., Duy, P.Q. (2015) Neurobehavioral features and targeted treatments in fragile X syndrome: Current insights and future directions. Engrami, vol. 37, br. 4, str. 5-26
|
|
1
|
Castrén, M., Lampinen, K.E., Miettinen, R., Koponen, E., Sipola, I., Bakker, C.E., Oostra, B.A., Castrén, E. (2002) BDNF regulates the expression of fragile X mental retardation protein mRNA in the hippocampus. Neurobiology of disease, 11(1): 221-9
|
|
1
|
Castrén, M.L. (2016) Cortical neurogenesis in fragile X syndrome. Frontiers in Bioscience, 8(1): 160-168
|
|
|
Collier, R. (2009) Drug development cost estimates hard to swallow. CMAJ, 180(3): 279-80
|
|
|
Curtis, L.M., Tonascia, S. (1986) Clinical trials: design, conduct, and analysis. USA: Oxford University Press
|
|
|
d`Antoni Simona,, Spatuzza, M., Bonaccorso, C.M., Musumeci, S.A., Ciranna, L., Nicoletti, F., Huber, K.M., Catania, M.V. (2014) Dysregulation of group-I metabotropic glutamate (mGlu) receptor mediated signalling in disorders associated with Intellectual Disability and Autism. Neuroscience & Biobehavioral Reviews, 46: 228-241
|
|
|
Darnell, J.C., Mostovetsky, O., Darnell, R.B. (2005) FMRP RNA targets: identification and validation. Genes, brain, and behavior, 4(6): 341-9
|
|
|
Darnell, J.C., Fraser, C.E., Mostovetsky, O., Stefani, G., Jones, T.A., Eddy, S.R., Darnell, R.B. (2005) Kissing complex RNAs mediate interaction between the Fragile-X mental retardation protein KH2 domain and brain polyribosomes. Genes Dev, 19(8): 903-18
|
|
1
|
de Diego-Otero, Y., Romero-Zerbo, Y., el Bekay, R., Decara, J., Sanchez, L., Rodriguez-de, F.F., del Arco-Herrera, I. (2009) Alpha-tocopherol protects against oxidative stress in the fragile X knockout mouse: an experimental therapeutic approach for the Fmr1 deficiency. Neuropsychopharmacology, 34(4): 1011-26
|
|
|
Dölen, G., Bear, M.F. (2009) Fragile x syndrome and autism: from disease model to therapeutic targets. Journal of Neurodevelopmental Disorders, 1(2): 133-140
|
|
|
Edbauer, D., Neilson, J.R., Foster, K.A., Wang, C., Seeburg, D.P., Batterton, M.N., Tada, T., Dolan, B.M., Sharp, P.A., Sheng, M. (2010) Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron, 65(3): 373-84
|
|
|
Emanuel, E.J. (2015) The solution to drug prices. New York Times
|
|
1
|
Endo, A. (1992) The discovery and development of HMG-CoA reductase inhibitors. Journal of lipid research, 33(11): 1569-82
|
|
|
Erickson, C., Budimirovic, D., i dr. (2016) Fragile X Targeted Pharmacotherapy: Lessons Learned and Future Directions. J Neurodev Disord., An invited review
|
|
1
|
Erickson, C.A., Ray, B., Maloney, B., Wink, L.K., Bowers, K., Schaefer, T.L., McDougle, C.J., Sokol, D.K., Lahiri, D.K. (2014) Impact of acamprosate on plasma amyloid-β precursor protein in youth: A pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. Journal of Psychiatric Research, 59: 220-228
|
|
|
Faqi, A. (2012) A Comprehensive Guide to Toxicology in Preclinical Drug Development. Waltham: Massachusetts: Academic Press
|
|
|
Friedman, L.M., Furberg, C.D., Demets, D., Reboussin, D.M., Granger, C.B. (2015) Fundamentals of Clinical Trials. USA: Springer
|
|
|
Froestl, W., Muhs, A., Pfeifer, A. (2012) Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors. Journal of Alzheimer's disease, 32(4): 793-887
|
|
|
Gantois, I., Pop, A.S., de Esch, C.E.F., Buijsen, R.A.M., Pooters, T., Gomez-Mancilla, B., Gasparini, F., Oostra, B.A., d`Hooge Rudi,, Willemsen, R. (2013) Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice. Behavioural Brain Research, 239: 72-79
|
|
1
|
Hagerman, R.J., Berry-Kravis, E., Kaufmann, W.E., Ono, M.Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., Picker, J., Gane, L., Tranfaglia, M. (2009) Advances in the treatment of fragile X syndrome. Pediatrics, 123(1): 378-90
|
|
|
Hagerman, R.J., Des-Portes, V., Gasparini, F., Jacquemont, S., Gomez-Mancilla, B. (2014) Translating Molecular Advances in Fragile X Syndrome Into Therapy. Journal of Clinical Psychiatry, 75(04): e294-e307
|
|
|
Hajós, M. (2014) Portraying Inhibition of Metabotropic Glutamate Receptor 5 in Fragile X Mice. Biological Psychiatry, 75(3): 177-178
|
|
|
Harony, H., Wagner, S. (2010) The contribution of oxytocin and vasopressin to mammalian social behavior: potential role in autism spectrum disorder. Neuro-Signals, 18(2): 82-97
|
|
1
|
Henderson, C., Wijetunge, L., Kinoshita, M. N., Shumway, M., Hammond, R. S., Postma, F. R., Brynczka, C., Rush, R., Thomas, A., Paylor, R., Warren, S. T., vanderklish P. W., Kind, P. C., Carpenter, R. L., Bear, M. F., Healy, A. M. (2012) Reversal of Disease-Related Pathologies in the Fragile X Mouse Model by Selective Activation of GABAB Receptors with Arbaclofen. Science Translational Medicine, 4(152): 152ra128-152ra128
|
|
|
Hinton, V.J., Brown, W.T., Wisniewski, K., Rudelli, R.D. (1991) Analysis of neocortex in three males with the fragile X syndrome. American journal of medical genetics, 41(3): 289-94
|
|
1
|
Iossifov, I., Ronemus, M., Levy, D., Wang, Z., Hakker, I., Rosenbaum, J., Yamrom, B., Lee, Y., Narzisi, G., Leotta, A., Kendall, J., Grabowska, E., Ma, B., Marks, S., Rodgers, L., Stepansky, A., Troge, J. (2012) De novo gene disruptions in children on the autistic spectrum. Neuron, 74(2): 285-99
|
|
|
Jacquemont, S., Curie, A., i dr. (2011) Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med, 3(64):64ra1
|
|
1
|
Jacquemont, S., Berry-Kravis, E., Hagerman, R., von Raison, F., Gasparini, F., Apostol, G., Ufer, M., Des, P.V., Gomez-Mancilla, B. (2014) The challenges of clinical trials in fragile X syndrome. Psychopharmacology, 231(6): 1237-50
|
|
1
|
Jeste, S. S., Geschwind, D. H. (2016) Clinical trials for neurodevelopmental disorders: At a therapeutic frontier. Science Translational Medicine, 8(321): 321fs1-321fs1
|
|
1
|
Kaufmann, W.E., Capone, G., Clarke, M., Budimirovic, D.B. (2008) Autism in genetic intellectual disability: Insights into idiopathic autism. u: Zimmerman A.W. [ur.] Autism: Current Theories and Evidence, Totowa, NJ: Humana Press Inc, 2008. p. 81-108
|
|
1
|
Kaufmann, W.E., Moser, H.W. (2000) Dendritic anomalies in disorders associated with mental retardation. Cerebral cortex, 10(10): 981-91
|
|
1
|
Lauterborn, J.C., Rex, C.S., Kramár, E., Chen, L.Y., Pandyarajan, V., Lynch, G., Gall, C.M. (2007) Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. Journal of neuroscience, 27(40): 10685-94
|
|
|
Lee, E.K., Kim, H.H., Kuwano, Y., Abdelmohsen, K., Srikantan, S., Subaran, S.S., Gleichmann, M., Mughal, M.R., Martindale, J.L., Yang, X., Worley, P.F., Mattson, M.P., Gorospe, M. (2010) hnRNP C promotes APP translation by competing with FMRP for APP mRNA recruitment to P bodies. Nature structural & molecular biology, 17(6): 732-9
|
|
|
Leeson, P.D., Springthorpe, B. (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nature reviews. Drug discovery, 6(11): 881-90
|
|
|
Mattisson, C., Bogren, M., Horstmann, V. (2012) Correspondence between clinical diagnoses of depressive and anxiety disorders and diagnostic screening via the Hopkins Symptom Check List-25 in the Lundby Study. Nordic Journal of Psychiatry, 67(3): 204-213
|
|
|
Paul, S.M., Mytelka, D.S., Dunwiddie, C.T., Persinger, C.C., Munos, B.H., Lindborg, S.R., Schacht, A.L. (2010) How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nature reviews. Drug discovery, 9(3): 203-14
|
|
|
Pop, A.S., Levenga, J., de Esch, C.E. F., Buijsen, R.A. M., Nieuwenhuizen, I.M., Li, T., Isaacs, A., Gasparini, F., Oostra, B.A., Willemsen, R. (2012) Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant. Psychopharmacology, 231(6): 1227-1235
|
|
|
Portes, des V., Kim, E., Koumaras, B., Playan, F.J., Slater, L., Zhu, L., Kalim, J., von Raison, F., Apostol, G. (2014) Mavoglurant in adolescent patients with fragile X syndrome: Results of a randomized, double-blind, placebo controlled study. u: 14th International Fragile X Conference, Orange County, CA, USA, July 16-20, [poster]
|
|
|
Pretto, D., Yrigollen, C.M., Tang, H., Williamson, J., Espinal, G., Iwahashi, C.K., Durbin-Johnson, B., Hagerman, R.J., Hagerman, P.J., Tassone, F. (2014) Clinical and molecular implications of mosaicism in FMR1 full mutations. Frontiers in Genetics, 5: 318
|
|
|
Rask-Andersen, M., Almén, M.S., Schiöth, H.B. (2011) Trends in the exploitation of novel drug targets. Nature reviews. Drug discovery, 10(8): 579-90
|
|
2
|
Russell, W.M., Burch, R.L. (1959) The principles of humane experimental technique. London: Methuen
|
|
1
|
Scharf, S.H., Jaeschke, G., Wettstein, J.G., Lindemann, L. (2015) Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome. Current Opinion in Pharmacology, 20: 124-134
|
|
|
Sherman, S. (2002) Epidemiology. u: Hagerman R.J., Hagerman P.J. [ur.] Fragile X syndrome: Diagnosis, treatment, and research, Baltimore, MD: Johns Hopkins University Press, 2002. p. 136-9
|
|
1
|
Sidorov, M.S., Auerbach, B.D., Bear, M.F. (2013) Fragile X mental retardation protein and synaptic plasticity. Molecular Brain, 6(1): 15
|
|
2
|
Sultana, R., Perluigi, M., Butterfield, A.D. (2006) Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: Insights into mechanism of neurodegeneration from redox proteomics. Antioxidants & redox signaling, 8(11-12): 2021-37
|
|
|
Todorović, Z., Prostran, M., Turza, K., editors (2012) Bioethics and Pharmacology: Ethics in Preclinical and Clinical Drug Development. India: Kerala, Transworld Research Network
|
|
|
Trivedi, R.R., Bhattacharyya, S. (2012) Constitutive internalization and recycling of metabotropic glutamate receptor 5 (mGluR5). Biochemical and biophysical research communications, 427(1): 185-90
|
|
|
Uutela, M., Lindholm, J., Rantamäki, T., Umemori, J., Hunter, K., Vaµikar, V., Castrén, M.L. (2014) Distinctive behavioral and cellular responses to fluoxetine in the mouse model for Fragile X syndrome. Frontiers in Cellular Neuroscience, 8: 150
|
|
1
|
Westmark, C.J., Malter, J.S. (2007) FMRP Mediates mGluR5-Dependent Translation of Amyloid Precursor Protein. PLoS Biology, 5(3): e52
|
|
|
Westmark, C.J. (2014) The quest for fragile X biomarkers. Molecular and Cellular Pediatrics, 1(1)1
|
|
|
|
|